Back to top
more

Mirum Pharmaceuticals (MIRM)

(Delayed Data from NSDQ)

$40.40 USD

40.40
357,420

+1.94 (5.04%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $40.40 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Will Mirum Pharmaceuticals, Inc. (MIRM) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

Mirum Pharmaceuticals (MIRM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FYC

Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FYC

Should First Trust Small Cap Core AlphaDEX ETF (FYX) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FYX

Mirum Pharmaceuticals (MIRM) Up 4.5% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is First Trust Small Cap Core AlphaDEX ETF (FYX) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FYX

Mirum (MIRM) Banks on Livmarli, Overdependence a Concern

by Zacks Equity Research

Mirum's (MIRM) lead drug, Livmarli, continues to generate steady sales. The recent label expansion of the drug should drive sales further. However, overdependence on Livmarli for revenues is a concern.

Mirum's (MIRM) Q2 Earnings Lag Estimates, Revenues Top

by Zacks Equity Research

Mirum's (MIRM) earnings miss estimates in the second quarter of 2024 while revenues beat the same. Livmarli drives year-over-year sales.

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of -8.33% and 4.43%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of -8.76% and 93.84%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Mirum Pharmaceuticals (MIRM) Surges 7.3%: Is This an Indication of Further Gains?

by Zacks Equity Research

Mirum Pharmaceuticals (MIRM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Mirum (MIRM) Gets EC Approval for Livmarli Label Expansion

by Zacks Equity Research

The European Commission approves Mirum's (MIRM) Livmarli for the treatment of progressive familial intrahepatic cholestasis in patients three months of age and older.

Mirum (MIRM) Rises More Than 30% in Past 3 Months: Here's Why

by Zacks Equity Research

The recent label expansion of Mirum's (MIRM) lead drug, Livmarli, is expected to drive sales in the upcoming quarters. The company's efforts to build its pipeline beyond Livmarli also hold promise.

Mirum (MIRM) Soars on Interim Data From Liver Disease Studies

by Zacks Equity Research

Mirum (MIRM) posts positive interim data from two phase IIb studies evaluating volixibat in patients with primary biliary cholangitis and primary sclerosing cholangitis. Stock rises.

Mirum Pharmaceuticals (MIRM) Soars 27.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Why Is Mirum Pharmaceuticals (MIRM) Down 3.4% Since Last Earnings Report?

by Zacks Equity Research

Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Mirum's (MIRM) Livmarli Aids Sales but Overdependence Concerns

by Zacks Equity Research

Mirum's (MIRM) lead drug, Livmarli, continues to generate steady sales. The recent label expansion of the drug should drive sales further. However, overdependence on Livmarli for revenues is a concern.

Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates

by Zacks Equity Research

Mirum's (MIRM) earnings and revenues miss estimates in the first quarter of 2024. Livmarli drives year-over-year sales.

Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Mirum Pharmaceuticals (MIRM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Mirum's (MIRM) Livmarli Receives FDA Nod for Expanded Use

by Zacks Equity Research

Mirum's (MIRM) Livmarli gets FDA approval for label expansion to include the treatment of cholestatic pruritus in patients aged five years and older with PFIC.

Mirum's (MIRM) Q4 Earnings Lag Estimates, Revenues Beat

by Zacks Equity Research

Mirum's (MIRM) earnings fall shy of estimates in the fourth quarter of 2023 while revenues beat the same.

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of -94.12% and 4.23%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Sarepta Therapeutics (SRPT) Moves 7.8% Higher: Will This Strength Last?

by Zacks Equity Research

Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.